Document:

AMENDMENT
      TO

    RESTRICTED
      STOCK AGREEMENT

     

    THIS
      AMENDMENT TO RESTRICTED STOCK AGREEMENT (“Amendment”) is
      made
      as of January 23, 2006, by and among Cleveland BioLabs, Inc., a Delaware
      corporation (the “Company”), and
      Yakov
      Kogan (the “Executive”).
      Capitalized terms not otherwise defined herein shall have the meaning ascribed
      to such terms in the Restricted Stock Agreement.

     

    R
      E C I T A L S

     

    WHEREAS, the
      Company and the Executive have entered into that certain Restricted Stock
      Agreement, dated as of July 5, 2003 (the “Restricted
      Stock Agreement”); and

     

    WHEREAS, the
      Company and the Executive wish to amend and restate the definition of “Qualified
      Public Offering” in its entirety and make certain other changes to the
      Restricted Stock Agreement;

     

    NOW, THEREFORE, for
      good
      and valuable consideration, the receipt and adequacy of which is hereby
      acknowledged, the parties hereto hereby agree as follows:

     

    1. Section
      6. The
      definition of “Qualified Public Offering” in Section 6 of the Restricted Stock
      Agreement is hereby amended and restated in its entirety to read as
      follows:

     

    “Qualified
      Public Offering”
means
      the sale in an underwritten public offering registered under the Securities
      Act
      of shares of the Company’s Common Stock approved by the Board resulting in net
      proceeds to the Company of no less than $7.5 million.”

     

    2. Section
      7.
      The
      following portion of Section 7 of the Restricted Stock Agreement is hereby
      amended and restated in its entirety to read as follows:

     

    “With
      a
      copy to:

     

    Katten
      Muchin Rosenman

    525
      West
      Monroe Street 

    Chicago,
      Illinois 60661

    Fax: (312) 577-8733

    Tel: (312) 902-5520

    Attn: Ram
      Padmanabhan, Esq.”

     

    3. No
      Amendment or Waiver. The
      execution, delivery and effectiveness of this Amendment shall not constitute
      an
      amendment or waiver of any other provision of the Restricted Stock Agreement.
      The terms of the Restricted Stock Agreement not affected, modified or changed
      by
      this Amendment shall remain in full force and effect.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4. References. Each
      reference in the Restricted Stock Agreement to “this Agreement”, “hereunder”,
“hereof”, “herein”, or words of like import shall mean and be a reference to the
      Restricted Stock Agreement as amended hereby, and each reference to the
      Restricted Stock Agreement in any other document, instrument or agreement shall
      mean and be a reference to the Restricted Stock Agreement as amended
      hereby.

     

    5. Counterparts. This
      Amendment may be executed in two counterparts, each of which shall be deemed
      an
      original, but both of which together shall constitute one and the same
      instrument. Facsimile signatures shall be accepted as originals.

     

    [Signature
      Page Follows]

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

     

    IN
      WITNESS WHEREOF, the
      undersigned or each of their respective duly authorized officers or
      representatives have set their hands hereunder effective upon the date
      referenced-above.

     

    
      	 	 	 
	 	
              THE
                COMPANY:

               

               

              Cleveland BioLabs,
                Inc.,
                a
                Delaware corporation

            
	 
 	 
 	 
 
	 	By:  	/s/ Michael
              Fonstein
	 	 	
              Michael
                Fonstein

              President
                and Chief Executive Officer

            
	 	 	 
	 	 	 
	 	THE EXECUTIVE:
	 	 	 
	 	 	 
	 	By: 	/s/ Yakov
              Kogan
	 	
              
Yakov
              KoganAMENDMENT
      TO

    RESTRICTED
      STOCK AGREEMENT

     

    THIS
      AMENDMENT TO RESTRICTED STOCK AGREEMENT (“Amendment”) is
      made
      as of January 23, 2006, by and among Cleveland BioLabs, Inc., a Delaware
      corporation (the “Company”), and
      Andrei Gudkov (the “Executive”). Capitalized
      terms not otherwise defined herein shall have the meaning ascribed to such
      terms
      in the Restricted Stock Agreement.

     

    RECITALS

     

    WHEREAS, the
      Company and the Executive have entered into that certain Restricted Stock
      Agreement, dated as of July 5, 2003 (the “Restricted
      Stock Agreement”); and
      

     

    WHEREAS, the
      Company and the Executive wish to amend and restate the definition of “Qualified
      Public Offering” in its entirety and make certain other changes to the
      Restricted Stock Agreement;

     

    NOW,
      THEREFORE, for
      good
      and valuable consideration, the receipt and adequacy of which is hereby
      acknowledged, the parties hereto hereby agree as follows:

     

    1. Section
      6. The
      definition of “Qualified Public Offering” in Section 6 of the Restricted Stock
      Agreement is hereby amended and restated in its entirety to read as
      follows:

     

    “Qualified
      Public Offering”
means
      the sale in an underwritten public offering registered under the Securities
      Act
      of shares of the Company’s Common Stock approved by the Board resulting in net
      proceeds to the Company of no less than $7.5 million.”

     

    2. Section
      7.
      The
      following portion of Section 7 of the Restricted Stock Agreement is hereby
      amended and restated in its entirety to read as follows:

     

    “With
      a
      copy to:

     

    Katten
      Muchin Rosenman

    525
      West
      Monroe Street 

    Chicago,
      Illinois 60661

    Fax: (312) 577-8733

    Tel: (312) 902-5520

    Attn: Ram
      Padmanabhan, Esq.”

     

    3. No
      Amendment or Waiver. The
      execution, delivery and effectiveness of this Amendment shall not constitute
      an
      amendment or waiver of any other provision of the Restricted Stock Agreement.
      The terms of the Restricted Stock Agreement not affected, modified or changed
      by
      this Amendment shall remain in full force and effect.

     

    4. References. Each
      reference in the Restricted Stock Agreement to “this Agreement”, “hereunder”,
“hereof”, “herein”, or words of like import shall mean and be a reference to the
      Restricted Stock Agreement as amended hereby, and each reference to the
Restricted
      Stock Agreement in any other document, instrument or agreement shall mean and
      be
      a
      reference to the Restricted Stock Agreement as amended hereby.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    5. Counterparts. This
      Amendment may be executed in two counterparts, each of which shall be deemed
      an
      original, but both of which together shall constitute one and the same
      instrument. Facsimile signatures shall be accepted as originals.

     

    [Signature
      Page Follows]

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, the
      undersigned or each of their respective duly authorized officers or
      representatives have set their hands hereunder effective upon the date
      referenced-above.

     

    
      	 	 	 
	 	 
	 	 	THE COMPANY:
	 	 	 
	 	 	Cleveland BioLabs,
              Inc.,
              a Delaware corporation
	 
 	 
 	 
 
	 	 	/s/ Michael
              Fonstein
	 	
              
By: Michael
              Fonstein
	 	President and Chief Executive Officer

    

     

    
       

      
        	 	 	 
	 	 
	 	 	THE EXECUTIVE:
	 
 	 
 	 
 
	 	 	/s/ Andrei
                Gudkov
	 	
                
By: Andrei
                GudkovAMENDMENT
      TO

    COMMON
      STOCKHOLDERS AGREEMENT

     

    THIS
      AMENDMENT TO COMMON STOCKHOLDERS AGREEMENT (“Amendment”) is
      made
      as of January 26, 2006, by and among Cleveland BioLabs, Inc., a Delaware
      corporation (the “Company”), and
      the
      Stockholders party thereto. Capitalized terms not otherwise defined herein
      shall
      have the meaning ascribed to such terms in the Common Stockholders
      Agreement.

     

    RECITALS

     

    WHEREAS, the
      Company and the Stockholders have entered into that certain Common Stockholders
      Agreement, dated as of July 1, 2004 (the “Common
      Stockholders Agreement”); and

     

    WHEREAS, the
      parties to the Common Stockholders Agreement wish to amend and restate Sections
      1(j) and 2(d) of the Common Stockholders Agreement in their
      entirety.

     

    NOW,
      THEREFORE, for
      good
      and valuable consideration, the receipt and adequacy of which is hereby
      acknowledged, the parties hereto hereby agree as follows:

     

    1. Section
      1(j). Section
      1(j) of the Common Stockholders Agreement is hereby amended and restated in
      its
      entirety to read as follows:

     

    “Qualified
      IPO”
means
      a
      fully underwritten firm commitment public offering of shares of Common Stock
      consummated pursuant to a registration statement declared effective under the
      Securities Act, other than an offering made in connection with a business
      acquisition or combination or an employee benefit plan, in which the aggregate
      gross proceeds to the Company after deducting underwriters’ discounts and
      commissions and related offering expenses equals or exceeds Fifteen Million
      Dollars ($15,000,000).”

     

    2. Section
      2(d).
      Section
      2(d) of the Common Stockholders Agreement is hereby amended and restated in
      its
      entirety to read as follows:

     

    “Notwithstanding
      the foregoing, the provisions of this Section 2 will terminate automatically
      and
      be of no further force and effect upon the consummation of a Qualified IPO
      or
      upon consummation of any equity financing or series of equity financings after
      January 1, 2006 in which the aggregate gross proceeds to the Company after
      deducting underwriters’ discounts and commissions and related offering expenses
      equals or exceeds Fifteen Million Dollars ($15,000,000); provided,
      however,
      for as
      long as CCF owns at least three percent (3%) of the shares of the Company on
      a
      fully diluted basis, CCF will be entitled to have one representative elected
      to
      the Board pursuant to the terms of this Section 2.”

     

    3. No
      Amendment or Waiver. The
      execution, delivery and effectiveness of this Amendment shall not constitute
      an
      amendment or waiver of any other provision of the Common Stockholders Agreement.
      The terms of the Common Stockholders Agreement not affected, modified or changed
      by this Amendment shall remain in full force and effect.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

       

    

    4. Counterparts. This
      Amendment may be executed in two or more counterparts,
      each of which shall be deemed an original, but all of which
      together
      shall constitute
      one and
      the same instrument. Facsimile signatures shall be accepted as
      originals.

     

    *
      * *
      *

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Signature
      Page Follows

     

    E

    IN
      WITNESS WHEREOF, the
      undersigned or each of their respective duly authorized officers or
      representatives have set their hands hereunder effective upon the date
      referenced-above.

     

    
      
        	 	 	 
	 	
                THE
                  COMPANY:

              
	 	 
	 	

                Cleveland
                  BioLabs,
                  Inc.,
                  a
                  Delaware
                  corporation

              
	 
 	 
 	 
 
	 	 	/s/ Michael
                Fonstein
	 	
                
By: Michael
                Fonstein
	 	
                Title: President
                  and Chief Executive  Officer

              

      

    

     

    [Signatures
      Continue on Next Page]

     

    
      
        
           

        

        
           

          
            

          

        

        
           

        

      

    

     

    
      	 	COMMON
              STOCKHOLDERS
	 	 
	 	 
	 	/s/ Michael Fonstein
	 	
              
Michael
              Fonstein
	 	 
	 	 
	 	/s/ Yakov
              Kogan
	 	
              
 Yakov
              Kogan
	 	 
	 	 
	 	/s/ Elena
              Feinstein
	 	
              

              Elena Feinstein
	 	 
	 	 
	 	/s/ George
              R. Stark
	 	
              
                

              

              George R. Stark

            
	 	 
	 	 
	 	/s/ Mikhail
              V. Chernov
	 	
              

              Mikhail V. Chernov
	 	 
	 	 
	 	/s/ Katerina
              Gurova
	 	
              

              Katerina Gurova
	 	 
	 	 
	 	/s/ Vadim
              Krivokrysenko
	 	
              

              Vadim Krivokrysenko

    

     

    [Signatures
      Continue on Next Page]

     

    
      
        
           

        

        
           

          
            

          

        

        
           

        

      

    

     

    
      
        	 	 	 
	
                ChemBridge
                  Corporation

              
	 	

                 

              
	 
 	 
 	 
 
	 	By: 
                	/s/ Sergey
                Altshtein
	 	
                
Name: Sergey
                Altshtein
	 	
                Title: President

              

      

    

    
      
        	 	 	 
	 	 	 
	 	The
                Cleveland Clinic Foundation 
	 
 	 
 	 
 
	 	 	 
	 	By: 
                	/s/ Michael
                P. O’Boyle
	 	
                
Name: Michael
                P. O’Boyle
	 	
                Title: Chief
                  Operating
                  Officer

              

      
        
          	 	 	 
	 
 	 
 	 
 
	 	 
                  	/s/ Michael
                  P. O’Boyle
	 	 	
                  
                    

                  

                   

                  Andrei Gudkov

                
	 	By:  	The Cleveland Clinic Foundation, 
	 	as
                  attorney-in-fact

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]